Arcturus Therapeutics Holdings Inc. (ARCT) stock forecast and price target
Price $8.36 · data as of November 13, 2026
12-month price target
Average target$23.80
Upside / downside+184.7%
Analysts10
ConsensusStrong buy
Low $9.00Average $23.80High $41.00
Gold marker: average target · white marker: today’s price ($8.36)
Analyst ratings
Strong buy 1Buy 10Hold 2Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-2.90 | −20.7% | $28M |
| Next fiscal year ends December 31, 2027 | $-3.33 | −15.0% | $32M |
| Next quarter ends December 31, 2026 | $-0.83 | +19.0% | $4M |
| Quarter after ends March 31, 2027 | $-0.88 | +7.6% | $2M |
Consensus of the analysts covering Arcturus Therapeutics, updated daily. In the last 30 days 2 estimates were raised and 0 lowered.
Frequently asked questions
What is the Arcturus Therapeutics stock price target?
The average 12-month target from 10 analysts is $23.80, 184.7% above the current price of $8.36 Targets range from $9.00 to $41.00.
Is Arcturus Therapeutics a buy according to analysts?
The consensus rating is “Strong buy” (1 strong buy, 10 buy, 2 hold). Ratings are opinions, not guarantees; this is not investment advice.
How much is Arcturus Therapeutics expected to earn?
Analysts expect EPS of $-2.90 for the fiscal year ending December 31, 2026 and $-3.33 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.